
Wade Iams, MD, MSCI, of Tennessee Oncology, explains how his team keeps patients on prophylactic strategies when starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer: repeated touches from multiple members of the care team over time, including his own counseling, nursing education at the injection visit, a call from a specialty pharmacist for the oral agent, and follow-up by advanced practice providers.







